Aktis Oncology, Inc., a clinical-stage company focused on advancing radiopharmaceutical therapies for cancers not addressed by current platforms, has announced that Mike Sherman has joined its Board of Directors as an independent director. The appointment marks a significant addition to Aktis as it pushes forward in developing novel treatments for difficult-to-treat cancers.
“Mike brings exceptional experience leading successful oncology companies through critical development milestones and strategic transactions,” said Matthew Roden, PhD, President and Chief Executive Officer of Aktis Oncology. “His impressive track record of value creation and deep understanding of the oncology landscape will be invaluable as we advance our innovative radiopharmaceutical platform, including the NECTINIUM-2 Phase Ib clinical trial evaluating AKY-1189 for the treatment of patients with locally advanced or metastatic urothelial carcinoma, triple negative breast cancer, and other Nectin-4 expressing tumors.”
Health Technology Insights: Minaris Opens New GMP Facility for Cell and Gene Therapies
With more than three decades in the life sciences industry, Mr. Sherman brings a wealth of knowledge and leadership to the board. He currently serves as an independent board member for Werewolf Therapeutics and Tolremo Therapeutics, two companies focused on the development of next-generation cancer treatments. Most recently, he was Chairman at Chimerix, where he led the company through its $935 million acquisition by Jazz Pharmaceuticals earlier in 2025. Before that, he served as CEO and board member at Chimerix, and previously held the same roles at Endocyte Inc. There, he played a key role in transforming the company from a $200 million valuation to a $2.1 billion acquisition by Novartis in 2018. That deal gave Novartis global rights to PLUVICTO, a radiopharmaceutical for advanced prostate cancer originally developed by Endocyte and now FDA-approved. Earlier in his career, Mr. Sherman was Endocyte’s CFO, where he helped guide the company through its IPO and multiple successful financings. He holds a degree in Economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth.
“I am excited to join the Aktis’ Board of Directors at such a pivotal time as the company is establishing itself as a leader in the field of radiopharmaceuticals,” said Mr. Sherman. “Aktis’ vision and proprietary miniprotein radioconjugate technology opens up new opportunities to create treatment options for patients facing difficult-to-treat cancers. The company has made terrific progress with its pipeline and with the Eli Lilly discovery collaboration, and I look forward to working with the exceptional team to advance these promising therapies to patients.”
Sherman’s addition to the board comes at a key moment for Aktis Oncology. With the ongoing NECTINIUM-2 study and a growing partnership portfolio, including the high-profile alliance with Eli Lilly, the company continues to position itself as an emerging force in the precision oncology space. His background in both executive leadership and large-scale biotech transactions adds strength to the company’s strategic direction as it aims to bring innovative therapies to underserved cancer populations.
Health Technology Insights: TransMedics Receives FDA IDE Approval to Initiate Next-Generation OCS Heart Trial
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
